Sucampo Pharmaceuticals Inc. A Stock Upgraded (SCMP)

NEW YORK ( TheStreet) -- Sucampo Pharmaceuticals Inc. A (Nasdaq: SCMP) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally poor debt management.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 4.3%. Since the same quarter one year prior, revenues rose by 15.1%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • Powered by its strong earnings growth of 140.00% and other important driving factors, this stock has surged by 84.42% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
  • SUCAMPO PHARMACEUTICALS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past two years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, SUCAMPO PHARMACEUTICALS INC reported poor results of -$0.43 versus -$0.07 in the prior year.
  • Currently the debt-to-equity ratio of 1.55 is quite high overall and when compared to the industry average, suggesting that the current management of debt levels should be re-evaluated. Regardless of the company's weak debt-to-equity ratio, SCMP has managed to keep a strong quick ratio of 2.29, which demonstrates the ability to cover short-term cash needs.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, SUCAMPO PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
.

Sucampo Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs based on prostones primarily in the Americas, Europe, and Asia. Sucampo Pharmaceuticals Inc. A has a market cap of $69.2 million and is part of the health care sector and drugs industry. Shares are up 66.8% year to date as of the close of trading on Wednesday.

You can view the full Sucampo Pharmaceuticals Inc. A Ratings Report or get investment ideas from our investment research center.
-- Written by a member of TheStreet RatingsStaff
null

If you liked this article you might like

Biotech Premarket Movers: Sucampo, Intellia, Cytokinetics

Big-Cap Tech Names, Biotechs, Oils Lifting Market

The Pockets of Speculative Action Have Dried Up

Shark Bites: Entry Points Are Scarce

Weak On High Volume: Sucampo Pharmaceuticals (SCMP)